Clinical Trial of TQB3002 in Patients With Advanced Cancers

Recruiting now · Phase 1

Conditions studied: Advanced Cancer

In brief

This is a Phase I study to evaluate the safety, tolerability, and efficacy of TQB3002 in subjects with advanced cancers

Key facts

Study ID

NCT06662760

Run by

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

People needed

150

Starts

2024-12-09

Expected to finish

2026-10-01

Last updated by the study team

2025-11-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects voluntarily joined this study, signed the informed consent form, and had good compliance；
• Age: ≥ 18 years old; Eastern Cooperative Oncology Group (ECOG) score: 0-1 ; Expected survival of more than 3 months；
• Histologically or cytologically diagnosed with advanced cancers
• Subjects with advanced malignancies who have failed standard therapy or lack effective treatment
• Major organs are functioning well；
• Female and male subjects of childbearing potential should agree to practice contraception for the duration of the study and for 6 months after the end of the study.

You may not qualify if…

• Current concomitant presence of other malignancies within 5 years prior to the first dose；
• Unresolved toxicity above CTCAE Grade 1 due to any prior anti-tumor therapy
• Significant surgical treatment, biopsy, or significant traumatic injury within 4 weeks prior to the first dose
• Long-term unhealed wounds or fractures
• Cerebrovascular accident (including transient ischemic attack, intracerebral hemorrhage, cerebral infarction), deep vein thrombosis, and pulmonary embolism within 6 months prior to the first dose
• Swallowing dysfunction, active gastrointestinal diseases or other diseases that significantly affect the absorption, distribution, metabolism and excretion of the study drug, or previous subtotal gastrectomy
• A history of psychotropic drug abuse and cannot be abstained from or have a mental disorder
• Subjects with any severe and/or uncontrolled disease

Where it is running

• Guangdong Provincial People's Hospital — Guangzhou, Guangdong, China (enrolling)
• Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center — Shenzhen, Guangdong, China
• Henan Cancer Hospital — Zhengzhou, Henan, China
• Jiangsu Province Hospital — Nanjing, Jiangsu, China
• The First Affiliated Hospital Of Nanchang University — Nanchang, Jiangxi, China
• Shanghai Pulmonary Hospital — Shanghai, Shanghai Municipality, China
• The Second Affiliated Hospital of Xi'an Jiaotong University — Xi’an, Shanxi, China
• The First Affiliated Hospital of Xi'an Jiao Tong University — Xi’an, Shanxi, China
• Sichuan Cancer Hospital — Chengdu, Sichuan, China
• Mianyang Central Hospital — Mianyang, Sichuan, China
• Yunnan Cancer Hospital — Kunming, Yunnan, China

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.